The tirzepatide 10mg dosage stage: what the chart shows and what to expect

Step 1: how tirzepatide's dose ladder is built, and where 10mg sits

The licensed titration schedule for tirzepatide in the UK runs in four-week increments: 2.5mg, then 5mg, then 7.5mg, then 10mg, then 12.5mg, then 15mg. The full tirzepatide dosage chart maps all six steps, but the logic running through all of them is the same: start low to let the gut adjust, increase steadily, and stop at the highest dose you tolerate well.

The 2.5mg starting dose exists primarily to reduce early nausea and gastrointestinal discomfort, it's a settling-in period for the body rather than a therapeutically active weight-management dose. By 10mg, most people are well past that adjustment phase. The clinical picture at 10mg is meaningfully different from the early weeks: appetite suppression is typically more established, gastric emptying is slower, and weight change is more pronounced.

Your prescriber decides when to move from 7.5mg to 10mg, usually after four weeks on the lower dose and a clinical review of how you've tolerated it. If side effects were significant at 7.5mg, they may hold you there longer. The schedule is a framework, not a conveyor belt.

Step 2: what the trial data shows at 10mg specifically

SURMOUNT-1, the pivotal phase 3 trial published in the New England Journal of Medicine, randomised over 2,500 adults with obesity across three tirzepatide arms (5mg, 10mg and 15mg) and placebo. At 72 weeks, participants on 10mg lost an average of around 19% of body weight, compared with roughly 3% in the placebo group. The 15mg arm averaged around 21%.

That 2-percentage-point gap between 10mg and 15mg matters, because it explains why some people stay at 10mg long-term rather than pushing to the maximum. If 10mg produces good results and you're tolerating it well, your prescriber may decide there's no clinical reason to increase further. The dosage decision at every level belongs to the prescriber, informed by your response and side-effect profile.

NICE's appraisal of tirzepatide, published in December 2024 and updated in September 2025, drew on this evidence in recommending tirzepatide for eligible adults as part of a managed weight programme. You can read the recommendations at NICE TA1026. The appraisal covers the full dose range, not 10mg in isolation, the licence treats the schedule as a whole.

Step 3: side effects and practical considerations at the 10mg stage

Most people find that gastrointestinal side effects (nausea, loose stools, reflux, reduced appetite to the point of forgetting meals) are most noticeable in the first week or two after each dose increase, then settle. By 10mg, having already moved through three increments, many people have a reasonable sense of how their body responds to titration. That said, each step can bring a fresh wave of GI symptoms, so the same caution applies: eat smaller meals, stay hydrated, and don't push through severe symptoms without speaking to your prescriber.

The NHS tirzepatide medicines page lists the full side-effect profile and signals that warrant urgent attention, including severe or persistent stomach pain that radiates to the back, a symptom the MHRA highlighted in its January 2026 Drug Safety Update on GLP-1 medicines and pancreatitis. That page is worth bookmarking.

Practically speaking: if you're ordering treatment in a month when a bank holiday or holiday falls mid-week, factor that into when your pen is due. Missing a weekly injection or taking it late is something to raise with your prescriber, not to manage by guessing. The Patient Information Leaflet that comes with your pen covers missed-dose guidance; your prescriber can advise on your specific situation. The Mounjaro dosage chart page has more on how the pen schedule interacts with timing questions.

Step 4: eligibility, cost context and next steps

Tirzepatide (sold as Mounjaro in the UK) is licensed for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea and cardiovascular disease among them. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full clinical picture; BMI alone is not sufficient.

Cost at 10mg is higher than at starter doses, which is a practical reality worth understanding before you begin treatment rather than discovering at month four. The Mounjaro price comparison page sets out the cost landscape honestly, including what a legitimate private prescription price covers and what it doesn't. The Mounjaro overview gives the broader clinical context for anyone earlier in the decision process.

If you're at the 10mg stage and wondering whether to continue, increase, or discuss alternatives, the right conversation is with your prescriber. At nume, a GPhC-registered prescriber on our clinical team reviews every repeat order before it's dispensed. You can also browse the frequently asked questions if you have general queries before starting. When you're ready, speak to our prescribers through a free consultation.